<DOC>
	<DOCNO>NCT01528735</DOCNO>
	<brief_summary>The objective trial investigate tolerability , safety , pharmacokinetics antiviral activity BI 207127 NA combination BI 201335 NA ribavirin 8 week Japanese treatment-naive patient chronic GT-1 HCV infection .</brief_summary>
	<brief_title>This Trial Evaluates Safety , Pharmacokinetic Profile Anti-viral Response BI 207127 BI 201335 Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : Chronic hepatitis C , diagnose positive antihepatitis C virus ( HCV ) antibody detect HCV ribonucleic acid ( RNA ) screen addition : 1. positive antiHCV antibody detect HCV RNA least 6 month prior screen ; , 2. liver biopsy consistent chronic HCV infection . HCV infection genotype 1 confirm genotypic test screen Therapyna√Øve interferon , pegylated interferon , ribavirin antiviral / immunomodulatory drug acute chronic HCV infection . Plasma HCV RNA = 100,000 IU/mL screen Exclusion criterion : Hepatitis C infection mixed genotype ( 1/2 , 1/3 , 1/4 ) diagnose genotypic test screen Human immunodeficiency virus ( HIV ) coinfection Decompensated liver disease , history decompensated liver disease Body weight &lt; 40 &gt; 125 kg screen Hemoglobin &lt; 12.0g/dL woman &lt; 13.0g/dL men screen White blood cell count &lt; 3000 cells/mm3 screen Absolute neutrophil count &lt; 1,500 cells/mm3 screen Platelet count &lt; 90,000 /mm3 screen Serum creatinine &gt; 1.5xUpper Limit Normal range ( ULN ) creatinine clearance =50 mL/min screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>